In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or perhaps the members are unable to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells per replicate have been analyzed, https://saddamu222ozk5.blogtov.com/profile